Search Result

Results for "

IBD

" in MedChemExpress (MCE) Product Catalog:

By Targets:	Aminopeptidase (1) Antibiotic (1) Apoptosis (5) Aryl Hydrocarbon Receptor (1) Aurora Kinase (3) Autophagy (2) Bacterial (5) CCR (2) COX (2) Dihydroorotate Dehydrogenase (4) E1/E2/E3 Enzyme (1) Endogenous Metabolite (1) Epigenetic Reader Domain (1) FXR (2) GCGR (2) GPR84 (1) HIV (1) HIV Integrase (1) IKK (1) Indoleamine 2,3-Dioxygenase (IDO) (3) Integrin (2) Interleukin Related (2) JAK (5) Na+/H+ Exchanger (NHE) (2) NF-κB (3) p38 MAPK (1) Parasite (3) Phosphodiesterase (PDE) (3) PIKfyve (1) Potassium Channel (1) Prostaglandin Receptor (3) RIP kinase (2) ROR (1) STAT (1) STING (1) TNF Receptor (1) TRP Channel (2) Virus Protease (3)
By Research Areas:	Cancer (10) Infection (8) Inflammation/Immunology (37) Metabolic Disease (4) Neurological Disease (3)

By Targets:

Aminopeptidase (1)

Antibiotic (1)

Apoptosis (5)

Aryl Hydrocarbon Receptor (1)

Aurora Kinase (3)

Autophagy (2)

Bacterial (5)

CCR (2)

COX (2)

Dihydroorotate Dehydrogenase (4)

E1/E2/E3 Enzyme (1)

Endogenous Metabolite (1)

Epigenetic Reader Domain (1)

FXR (2)

GCGR (2)

GPR84 (1)

HIV (1)

HIV Integrase (1)

IKK (1)

Indoleamine 2,3-Dioxygenase (IDO) (3)

Integrin (2)

Interleukin Related (2)

JAK (5)

Na+/H+ Exchanger (NHE) (2)

NF-κB (3)

p38 MAPK (1)

Parasite (3)

Phosphodiesterase (PDE) (3)

PIKfyve (1)

Potassium Channel (1)

Prostaglandin Receptor (3)

RIP kinase (2)

ROR (1)

STAT (1)

STING (1)

TNF Receptor (1)

TRP Channel (2)

Virus Protease (3)

By Research Areas:

Cancer (10)

Infection (8)

Inflammation/Immunology (37)

Metabolic Disease (4)

Neurological Disease (3)

Inhibitors & Agonists

Peptides

Inhibitory Antibodies

Natural
Products

Recombinant Proteins

Cat. No.	Product Name	Target	Research Areas	Chemical Structure

HY-151435

CCR6 antagonist 1 2 Publications Verification	CCR	Inflammation/Immunology
CCR6 antagonist 1 is a CCR6 antagonist that inhibits the CCL20/CCR6 axis. CCR6 antagonist 1 can be used in the research of autoimmune-mediated inflammatory diseases, such as inflammatory bowel diseases (IBDs) .

HY-12820

Sibofimloc 1 Publications Verification Antibiotic-202	Bacterial Antibiotic	Infection
Sibofimloc (Antibiotic-202) is a first-in-class, gut-restricted, orally active FimH adhesion inhibitor extracted from patent WO2014100158A1, Compound Example 202. Sibofimloc has anti-bacterial infective activity. Sibofimloc is developed for inflammatory bowel disease (IBD) .

HY-16640

TCJL37	JAK	Inflammation/Immunology
TCJL37 is a potent, selective, and orally bioavailable TYK2 inhibitor with a K_i of 1.6 nM. TCJL37 can be used for the research of inflammatory bowel diseases (IBD) .

HY-118795

SC-22716	Aminopeptidase	Inflammation/Immunology
SC-22716 is a potent, competitive, reversible inhibitor of human LTA₄ hydrolase, with an IC₅₀ of 0.20 µM. SC-22716 has potential for the research of inflammatory bowel disease (IBD) and psoriasis .

HY-155199

PDE1-IN-5	Phosphodiesterase (PDE)	Inflammation/Immunology
PDE1-IN-5 (Compound 10c) is a selective PDE1C inhibitor (IC₅₀: 15 nM). PDE1-IN-5 has anti- inflammatory activity, and inhibits expression of iNOS, TNF-α, IL-1α, IL-1β, and IL-6 induced by LPS. PDE1-IN-5 has anti-inflammatory bowel disease (IBD) effects in the dextran sodium sulfate (DSS)-Induced colitis mice model. PDE1-IN-5 can be used for research of IBD .

HY-P2221

Glepaglutide ZP1848	GCGR	Inflammation/Immunology
Glepaglutide (ZP1848), a long-acting GLP-2 analogue, is a potent GLP-2R agonist. Glepaglutide reduces faecal output and increases intestinal absorption. Glepaglutide alleviates small intestinal inflammation. Glepaglutide can be used in the research of inflammatory bowel disease (IBD) and Crohn’s disease .

HY-P2221B

Glepaglutide acetate ZP1848 acetate	GCGR	Inflammation/Immunology
Glepaglutide (ZP1848) acetate, a long-acting GLP-2 analogue, is a potent GLP-2R agonist. Glepaglutide acetate reduces faecal output and increases intestinal absorption. Glepaglutide acetate alleviates small intestinal inflammation. Glepaglutide acetate can be used in the research of inflammatory bowel disease (IBD) and Crohn’s disease .

HY-151174

PDE4-IN-12	Phosphodiesterase (PDE)	Inflammation/Immunology
PDE4-IN-12 is a potent pan-PDE4 inhibitor, with IC₅₀s of 3.5 and 15 nM for PDE4 and PDE7, respectively (SI=2.71 and 4.27, respectively). PDE4-IN-12 shows well tolerated, can be used in study of inflammatory bowel diseases (IBDs) .

HY-155680

BET BD2-IN-1	Epigenetic Reader Domain	Inflammation/Immunology
BET BD2-IN-1 (compound 45) is a potent and selective inhibitor of BET BD2 (IC₅₀=1.6 nM). BET BD2-IN-1 inhibits the differentiation of Th17 cells by decreasing the activation of STAT3 and NF-κB. BET BD2-IN-1 is used in psoriasis and inflammatory bowel disease (IBD) research .

HY-155782

Zharp2-1	RIP kinase	Inflammation/Immunology
Zharp2-1 is an oral effective RIPK2 inhibitor, highly associated with inflammatory bowel disease (IBD). Zharp2-1 blocker muramyl dipeptide (MDP) induces growth of mononuclear cells and induces inflammatory cell factor infection. Zharp2-1 attenuates MDP-induced small inguinal peritonitis, or ameliorates by DNBS-induced large inguinal conjunctivitis .

HY-13545B

ABT-510 acetate	Apoptosis	Inflammation/Immunology Cancer
ABT-510 acetate is an anti-angiogenic TSP peptide (Thrombospondin-1 analogue) that induces apoptosis and inhibits ovarian tumour growth in an orthotopic, syngeneic model of epithelial ovarian cancer. ABT-510 acetate also reduces angiogenesis and inflammatory responses in a murine model of inflammatory bowel disease. ABT-510 acetate can be used in studies of cancer (particularly epithelial ovarian cancer) and inflammatory bowel disease (IBD) .

HY-13545

ABT-510	Apoptosis	Inflammation/Immunology Cancer
ABT-510 is an anti-angiogenic TSP peptide (Thrombospondin-1 analogue) that induces apoptosis and inhibits ovarian tumour growth in an orthotopic, syngeneic model of epithelial ovarian cancer. ABT-510 also reduces angiogenesis and inflammatory responses in a murine model of inflammatory bowel disease. ABT-510 can be used in studies of cancer (particularly epithelial ovarian cancer) and inflammatory bowel disease (IBD) .

HY-160477

DC-SX029	PIKfyve NF-κB IKK	Inflammation/Immunology
DC-SX029 is a potent SNX10 protein-protein interaction (PPI) inhibitor with an estimated K_D constant of ~0.935 μM by surface plasmon resonance (SPR). DC-SX029 blocks the SNX10-PIKfyve interaction, thereby decreased the TBK1/c-Rel signaling activation. DC-SX029 does not affect the protein level of SNX10. DC-SX029 has the potential for inflammatory bowel disease (IBD) research .

HY-107831

5-Acetylsalicylic acid 1 Publications Verification	Others	Inflammation/Immunology
5-Acetylsalicylic acid has anti-inflammatory and is considered to be the active agent in inflammatory bowel disease (IBD) .

HY-105092

Tetomilast OPC-6535	Phosphodiesterase (PDE)	Inflammation/Immunology
Tetomilast (OPC-6535) is a PDE4 inhibitor with potential for the research of inflammatory bowel disease (IBD) and chronic obstructive pulmonary disease (COPD).

HY-149642

hDHODH-IN-13	Dihydroorotate Dehydrogenase	Others
hDHODH-IN-13 (compound w2) is an inhibitor of human dihydroorotate dehydrogenase (hDHODH) with an IC₅₀ value of 173.4 nM. hDHODH-IN-13 can be used in the research of *IBD* .

HY-142834

RORγt/DHODH-IN-2	ROR Dihydroorotate Dehydrogenase	Inflammation/Immunology
RORγt/DHODH-IN-2 (compound 1) is a potent dual RORγt/DHODH inhibitor. RORγt/DHODH-IN-2 can be used for inflammatory bowel disease (IBD) research .

HY-P99184

Abrilumab	Integrin	Infection Inflammation/Immunology Cancer
Abrilumab is a fully human monoclonal antibody directed against α4β7. Abrilumab selectively binds the α4β7 integrin heterodimer. Abrilumab can be used for the research of inflammatory bowel disease (IBD) .

HY-15707

NS6180	Potassium Channel	Inflammation/Immunology
NS6180 is a new orally active KCa3.1 channel inhibitor. NS6180 inhibits cloned human KCa3.1 channels with an IC₅₀value of 9 nM. NS6180 can be used for the research of inflammatory bowel disease (IBD) .

HY-14908

Vidofludimus 1 Publications Verification 4sc-101; SC12267	Dihydroorotate Dehydrogenase Interleukin Related FXR	Infection Inflammation/Immunology
Vidofludimus is an orally active inhibitor for dihydroorotate dehydrogenase (DHODH) and also is a novel modulator for farnesoid X receptor (FXR). Vidofludimus, as an immunomodulatory agent, can be used for the research of autoimmune disorders such as inflammatory bowel disease (IBD). Vidofludimus also can be used for the research of fatty liver by targeting FXR .

HY-19667

BMS-561392 DPC 333	TNF Receptor	Inflammation/Immunology
BMS-561392 is a TNF alpha-converting enzyme (TACE) inhibitor. BMS-561392 is also an ADAM17 blocker. BMS-561392 can be used for research of inflammatory bowel disease .

HY-157211

Anti-inflammatory agent 66	NF-κB p38 MAPK	Inflammation/Immunology
Anti-inflammatory agent 66 (compound 8) is a pterostilbene derivative with anti-inflammatory activity. Anti-inflammatory agent 66 inhibits pro-inflammatory cytokines by blocking the LPS-induced NF-κB/MAPK signaling pathway and effectively alleviates DSS-induced acute colitis in mice .

HY-14908A

Vidofludimus hemicalcium 4sc-101 hemicalcium; SC12267 hemicalcium	Dihydroorotate Dehydrogenase Interleukin Related FXR	Infection Inflammation/Immunology
Vidofludimus (4sc-101; SC12267) hemicalcium is an orally active inhibitor for dihydroorotate dehydrogenase (DHODH) and also is a novel modulator for farnesoid X receptor (FXR). Vidofludimus hemicalcium, as an immunomodulatory agent, can be used for the research of autoimmune disorders such as inflammatory bowel disease (IBD). Vidofludimus hemicalcium also can be used for the research of fatty liver by targeting FXR .

HY-115497

BRD5529	E1/E2/E3 Enzyme	Infection Inflammation/Immunology
BRD5529 is an effective dose-dependent CARD9-TRIM62 protein–protein interaction (PPI) inhibitor with an IC₅₀ value of 8.6 μM. BRD5529 has potency and complete inhibition of CARD9 ubiquitinylation in vitro, also has favorable solubility. BRD5529 can be used for the research of inflammatory bowel disease (IBD) such as Crohn’s disease (CD) and ulcerative colitis (UC) .

HY-P9984

Etrolizumab rhuMAb Beta7; RG7413; PRO145223	Integrin	Cancer
Etrolizumab (rhuMAb Beta7) is a gut-selective, anti-β7 integrin monoclonal antibody. Etrolizumab is specific targeting of the β7 subunit of α4β7 and αEβ7 integrins with K_i values of 18 nM and 1800 pM for Human α4β7 and Human αEβ7-293, respectively. Etrolizumab can be used in research of inflammatory bowel disease (IBD) .

HY-131064

RIPK3-IN-1 1 Publications Verification	RIP kinase	Inflammation/Immunology
RIPK3-IN-1 is a RIPK3 type II DFG-out inhibitor with an IC₅₀ of 9.1 nM. RIPK3-IN-1 inhibits RIPK1 and RIPK2 with IC₅₀s of 5.5 and >10 μM. RIPK3-IN-1 is also a c-Met kinase inhibitor with an IC₅₀ of 1.1 μM .

HY-123763

MLN3126	CCR	Inflammation/Immunology
MLN3126 is an orally active and potent CCR9 antagonist. MLN3126 inhibits CCL25-induced calcium mobilization and chemotaxis of mouse primary thymocytes, wiht an IC₅₀ value of 6.3 nM for calcium influx .

HY-W028393

Indole-3-pyruvic acid	Endogenous Metabolite Aryl Hydrocarbon Receptor	Neurological Disease Inflammation/Immunology
Indole-3-pyruvic acid, a keto analogue of tryptophan, is an orally active AHR agonist. Indole-3-pyruvic acid has antioxidant properties, and can be used in the research of inflammation, anxiety .

HY-155321

NXT-10796

Prostaglandin Receptor Cancer

NXT-10796 is orally active, intestinally restricted EP4 receptor agonist .

NXT-10796	Prostaglandin Receptor	Cancer
NXT-10796 is orally active, intestinally restricted EP4 receptor agonist .

HY-P2797

Chitinase, serratia marcescens AMCase	Bacterial	Metabolic Disease Inflammation/Immunology
Chitinase (EC 3.2.1.14) has partial lysozyme activity and is widely found in bacteria, fungi, animals and some plants. Chitinase belongs to the glycosyl hydrolase family. Chitinase catalyzes chito-oligosaccharide hydrolysis. Chitinases also can serve as prognostic biomarkers of disease progression. Chitinase can be used in the research of pathogenesis of various human fibrotic and inflammatory disorders, particularly those of the lung (idiopathic pulmonary fibrosis, chronic obstructive pulmonary disease, sarcoidosis, and asthma) and the gastrointestinal tract (inflammatory bowel diseases (IBDs) and colon cancer) .

HY-153094

BDM-2	HIV HIV Integrase	Infection
BDM-2 is an IN-LEDGF allosteric inhibitor (INLAI) of HIV-1 integrase (IN refers to integrase) (IC₅₀=47 nM) with potent anti-Retroviral (ARV) activity. BDM-2 shows IN multimerization activation effect with an AC₅₀ value of 20 nM. BDM-2 blocks the interaction between the catalytic core domain of IN (IN-CCD) and the Integrase binding domain of LEDGF/p75 (IBD), with an IC₅₀ value of 0.15 μM. BDM-2 exhibits highly selective and favorable cytotoxicity .

HY-109148

Izencitinib TD-1473; JNJ-8398	JAK	Inflammation/Immunology
Izencitinib (TD-1473) is an orally active, non-selective and gut-restricted JAK inhibitor. Izencitinib (TD-1473) can be used in the study for ulcerative colitis .

HY-151262

JAK-IN-23	JAK STING NF-κB STAT	Inflammation/Immunology
JAK-IN-23 is an orally active double inhibitor of JAK/STAT and NF-κB. JAK-IN-23 can inhibit JAK1/2/3 with IC₅₀ values of 8.9 nM, 15 nM and 46.2 nM, respectively. JAK-IN-23 has potent inhibitory activities against interferon-stimulated genes (ISG) and NF-κB pathways with IC₅₀ values of 3.3 nM and 150.7 nM, respectively. JAK-IN-23 has great anti-inflammatory that decreases the release of various proinflammatory factors. JAK-IN-23 can be used for the research of inflammatory bowel disease (IBD) .

HY-108017

Ferric maltol	Others	Metabolic Disease
Ferric maltol is an orally active complex of a single ferric ion (Fe ³⁺). Ferric maltol has tha potential for iron deficiency anemia treatment in inflammatory bowel disease .

HY-143884

JAK2/TYK2-IN-1	JAK	Inflammation/Immunology
JAK2/TYK2-IN-2 is a potent and selective TYK2 inhibitor with IC₅₀ values of 9 and 157 nM for TYK2 and JAK2, respectively. JAK2/TYK2-IN-2 has anti-inflammatory activity .

HY-120469

2,6-Dichloro-N-(2-(cyclopropanecarboxamido)pyridin-4-yl)benzamide	JAK	Inflammation/Immunology
GDC-046 is a potent, selective, and orally bioavailable TYK2 inhibitor with K_is of 4.8, 0.7, 0.7, and 0.4 nM for TYK2, JAK1, JAK2, and JAK3, respectively .

HY-135303

GLPG1205 1 Publications Verification	GPR84	Inflammation/Immunology
GLPG1205 is potent, selective and orally active GPR84 (a G-protein-coupled receptor) antagonist with a favorable PK/PD profile. GLPG1205 has anti-inflammatory activity and is used for the treatment of pulmonary fibrosis . GLPG1205 is a click chemistry reagent, it contains an Alkyne group and can undergo copper-catalyzed azide-alkyne cycloaddition (CuAAc) with molecules containing Azide groups.

HY-147105

LRH-1 modulator-1	Others	Inflammation/Immunology
LRH-1 modulator-1 (compound 6N) is a potent LRH-1 (liver receptor homolog-1) modulator/agonist. LRH-1 modulator-1 shows anti-inflammatory effects in intestinal organoids. LRH-1 modulator-1 induces anti-inflammatory cytokine IL-10, and reduces inflammatory cytokine IL-1b and TNFa .

HY-N0110

Palmatine chloride 5 Publications Verification	Indoleamine 2,3-Dioxygenase (IDO) Virus Protease Aurora Kinase Apoptosis Bacterial Parasite	Infection Neurological Disease Metabolic Disease Inflammation/Immunology Cancer
Palmatine chloride is an orally active and irreversible indoleamine 2,3-dioxygenase 1 (IDO-1) inhibitor with IC₅₀s of 3 μM and 157μM against HEK 293-hIDO-1 and rhIDO-1, respectively. Palmatine chloride can also inhibit West Nile virus (WNV) NS2B-NS3 protease in an uncompetitive manner with an IC₅₀ of 96 μM. Palmatine chloride shows anti-cancer, anti-oxidation, anti-inflammatory, neuroprotection, antibacterial, anti-viral activities .

HY-N0110B

Palmatine hydroxide 5 Publications Verification	Indoleamine 2,3-Dioxygenase (IDO) Virus Protease Aurora Kinase Apoptosis Bacterial Parasite	Infection Neurological Disease Metabolic Disease Inflammation/Immunology Cancer
Palmatine hydroxide is an orally active and irreversible indoleamine 2,3-dioxygenase 1 (IDO-1) inhibitor with IC₅₀s of 3 μM and 157μM against HEK 293-hIDO-1 and rhIDO-1, respectively. Palmatine hydroxide can also inhibit West Nile virus (WNV) NS2B-NS3 protease in an uncompetitive manner with an IC₅₀ of 96 μM. Palmatine hydroxide shows anti-cancer, anti-oxidation, anti-inflammatory, neuroprotection, antibacterial, anti-viral activities .

HY-N0110R

Palmatine chloride (Standard)	Apoptosis Virus Protease Indoleamine 2,3-Dioxygenase (IDO) Parasite Bacterial Aurora Kinase	Cancer
Palmatine (chloride) (Standard) is the analytical standard of Palmatine (chloride). This product is intended for research and analytical applications. Palmatine chloride is an orally active and irreversible indoleamine 2,3-dioxygenase 1 (IDO-1) inhibitor with IC₅₀s of 3 μM and 157μM against HEK 293-hIDO-1 and rhIDO-1, respectively. Palmatine chloride can also inhibit West Nile virus (WNV) NS2B-NS3 protease in an uncompetitive manner with an IC₅₀ of 96 μM. Palmatine chloride shows anti-cancer, anti-oxidation, anti-inflammatory, neuroprotection, antibacterial, anti-viral activities .

HY-101840

EIPA Maximum Cited Publications 40 Publications Verification L593754; MH 12-43; Ethylisopropylamiloride	TRP Channel Prostaglandin Receptor Autophagy COX Na+/H+ Exchanger (NHE)	Inflammation/Immunology Cancer
EIPA (L593754) is an orally active TRPP3 channel inhibitor with an IC₅₀ of 10.5 μM. EIPA also enhances autophagy by inhibiting Na ⁺/H ⁺-exchanger 3 (NHE3). EIPA inhibits macropinocytosis as well. EIPA can be used in the research of inflammation and cancers, such as gastric cancer, colon carcinoma, pancreatic carcinoma .

HY-101840A

EIPA hydrochloride Maximum Cited Publications 40 Publications Verification L593754 hydrochloride; MH 12-43 hydrochloride; Ethylisopropylamiloride hydrochloride	TRP Channel Autophagy COX Prostaglandin Receptor Na+/H+ Exchanger (NHE)	Inflammation/Immunology Cancer
EIPA (L593754) hydrochloride is an orally active TRPP3 channel inhibitor with an IC₅₀ of 10.5 μM. EIPA hydrochloride also enhances autophagy by inhibiting Na ⁺/H ⁺-exchanger 3 (NHE3). EIPA hydrochloride inhibits macropinocytosis as well. EIPA hydrochloride can be used in the research of inflammation and cancers, such as gastric cancer, colon carcinoma, pancreatic carcinoma .

Cat. No.	Product Name	Target	Research Area

HY-P2221B

Glepaglutide acetate ZP1848 acetate	GCGR	Inflammation/Immunology
Glepaglutide (ZP1848) acetate, a long-acting GLP-2 analogue, is a potent GLP-2R agonist. Glepaglutide acetate reduces faecal output and increases intestinal absorption. Glepaglutide acetate alleviates small intestinal inflammation. Glepaglutide acetate can be used in the research of inflammatory bowel disease (IBD) and Crohn’s disease .

HY-13545B

ABT-510 acetate	Apoptosis	Inflammation/Immunology Cancer
ABT-510 acetate is an anti-angiogenic TSP peptide (Thrombospondin-1 analogue) that induces apoptosis and inhibits ovarian tumour growth in an orthotopic, syngeneic model of epithelial ovarian cancer. ABT-510 acetate also reduces angiogenesis and inflammatory responses in a murine model of inflammatory bowel disease. ABT-510 acetate can be used in studies of cancer (particularly epithelial ovarian cancer) and inflammatory bowel disease (IBD) .

HY-P2221

Glepaglutide ZP1848	GCGR	Inflammation/Immunology
Glepaglutide (ZP1848), a long-acting GLP-2 analogue, is a potent GLP-2R agonist. Glepaglutide reduces faecal output and increases intestinal absorption. Glepaglutide alleviates small intestinal inflammation. Glepaglutide can be used in the research of inflammatory bowel disease (IBD) and Crohn’s disease .

HY-13545

ABT-510	Apoptosis	Inflammation/Immunology Cancer
ABT-510 is an anti-angiogenic TSP peptide (Thrombospondin-1 analogue) that induces apoptosis and inhibits ovarian tumour growth in an orthotopic, syngeneic model of epithelial ovarian cancer. ABT-510 also reduces angiogenesis and inflammatory responses in a murine model of inflammatory bowel disease. ABT-510 can be used in studies of cancer (particularly epithelial ovarian cancer) and inflammatory bowel disease (IBD) .

HY-143884

JAK2/TYK2-IN-1	JAK	Inflammation/Immunology
JAK2/TYK2-IN-2 is a potent and selective TYK2 inhibitor with IC₅₀ values of 9 and 157 nM for TYK2 and JAK2, respectively. JAK2/TYK2-IN-2 has anti-inflammatory activity .

Species:	Human (2) Mouse (1) Cynomolgus (2) Canine (1)
Tag:	His (5) Avi (1) Fc (1)
Source:	HEK293 (6)

Cat. No.	Compare	Product Name	Species	Source

HY-P78470

	IL-23R Protein, Human (HEK293, mFc) IBD17; IL-23 R; IL-23 receptor	Human	HEK293
	IL-23R Protein, critical in immune response, forms the interleukin-23 receptor by associating with IL12RB1. Binding to IL23, it activates T-cells, NK cells, and potentially macrophage/myeloid cells through Jak-Stat signaling. IL23, involved in innate and adaptive immunity, contributes to acute infection response. Associated with autoimmune diseases and tumorigenesis, IL-23R, in the presence of IL12RB1, forms a heterodimeric IL-23 receptor, interacting with JAK2 and activating STAT3. IL-23R Protein, Human (HEK293, mFc) is the recombinant human-derived IL-23R protein, expressed by HEK293, with C-mFc labeled tag. The total length of IL-23R Protein, Human (HEK293, mFc) is 332 a.a., with molecular weight of 80-115 kDa.

HY-P701011

	IL-23R Protein, Canine (HEK293, His) IBD17; IL-23 R; IL-23 receptor	Canine	HEK293
	IL-23R protein and IL12RB1 form interleukin 23 receptor, which is the key binding site of IL23. IL-23R mediates stimulation of T cells, NK cells, and possibly macrophages/myeloid cells, activating the Jak-Stat signaling cascade. IL-23R Protein, Canine (HEK293, His) is the recombinant canine-derived IL-23R protein, expressed by HEK293 , with C-His labeled tag. The total length of IL-23R Protein, Canine (HEK293, His) is 331 a.a., with molecular weight of 55-70 kDa.

HY-P700889

	IL-23R Protein, Cynomolgus (HEK293, C-His) IBD17; IL-23 R; IL-23 receptor	Cynomolgus	HEK293
	IL-23R protein and IL12RB1 form interleukin 23 receptor, which is the key binding site of IL23. IL-23R mediates stimulation of T cells, NK cells, and possibly macrophages/myeloid cells, activating the Jak-Stat signaling cascade. IL-23R Protein, Cynomolgus (HEK293, C-His) is the recombinant cynomolgus-derived IL-23R protein, expressed by HEK293 , with C-His labeled tag. The total length of IL-23R Protein, Cynomolgus (HEK293, C-His) is 330 a.a., with molecular weight of 60-80 kDa.

HY-P700746

	IL-23R Protein, Mouse (HEK293, His) IBD17; IL-23 R; IL-23 receptor; Il23r; Interleukin-23 receptor	Mouse	HEK293
	IL-23R protein and IL12RB1 form interleukin 23 receptor, which is the key binding site of IL23. IL-23R mediates stimulation of T cells, NK cells, and possibly macrophages/myeloid cells, activating the Jak-Stat signaling cascade. IL-23R Protein, Mouse (HEK293, His) is the recombinant mouse-derived IL-23R protein, expressed by HEK293 , with C-His labeled tag. The total length of IL-23R Protein, Mouse (HEK293, His) is 351 a.a., with molecular weight of 60-80 kDa.

HY-P700741

IL-10R alpha Protein, Cynomolgus (HEK293, His)

IL-10RA; IL10RA; IL10R; IL-10R1; IL-10R subunit 1; CDw210a; HIL-10R; IBD28; IL-10 R alpha
Cynomolgus HEK293

HY-P78464

	IL-10R alpha Protein, Human (HEK293, His-Avi) IL-10RA; IL10RA; IL10R; IL-10R1; IL-10R subunit 1; CDw210a; HIL-10R; IBD28; IL-10 R alpha	Human	HEK293
	IL-10R alpha protein is an IL10 cytokine surface receptor that is involved in IL10-mediated inflammation and immune regulation and inhibits the synthesis of pro-inflammatory cytokines. IL-10R alpha Protein, Human (HEK293, His-Avi) is expressed by HEK 293 cells and has a transmembrane region (V236-L256) with a His and Avi tag at the C-terminus.

Inquiry Online

Your information is safe with us. * Required Fields.

MCE Japan Authorized Agent ナミキ商事株式会社コスモ・バイオ株式会社
Salutation			Country or Region *
Applicant Name *			Organization Name *
Department *
Email Address *			Product Name *
Cat. No.			Requested quantity *
Phone Number *
Remarks